Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.86−0.03 (-0.10%)
Close on Nov 16, 2026Market cap $164.49BP/E 38.0Yield 5.96%
Pfizer operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pfizer's operating cash flow for the twelve months ending Jun 28, 2026 was $13.40B, down 11.8% year over year. For fiscal 2025 it was $11.70B, down 8.2% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $32.58B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.70B | -8.2% |
| FY2024 | Dec 31, 2024 | $12.74B | +46.5% |
| FY2023 | Dec 31, 2023 | $8.70B | -70.3% |
| FY2022 | Dec 31, 2022 | $29.27B | -10.2% |
| FY2021 | Dec 31, 2021 | $32.58B | +126.2% |
| FY2020 | Dec 31, 2020 | $14.40B | +14.4% |
| FY2019 | Dec 31, 2019 | $12.59B | -20.5% |
| FY2018 | Dec 31, 2018 | $15.83B | -5.8% |
| FY2017 | Dec 31, 2017 | $16.80B | +3.8% |
| FY2016 | Dec 31, 2016 | $16.19B | +10.2% |
| FY2015 | Dec 31, 2015 | $14.69B | -14.0% |
| FY2014 | Dec 31, 2014 | $17.08B | -3.4% |
| FY2013 | Dec 31, 2013 | $17.68B | +5.6% |
| FY2012 | Dec 31, 2012 | $16.75B | -17.3% |
| FY2011 | Dec 31, 2011 | $20.24B | +76.7% |
| FY2010 | Dec 31, 2010 | $11.45B | -30.9% |
| FY2009 | Dec 31, 2009 | $16.59B | -9.1% |
| FY2008 | Dec 31, 2008 | $18.24B | +36.6% |
| FY2007 | Dec 31, 2007 | $13.35B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 28, 2026 | $835.00M | – |
| Q1 FY2026 | Mar 29, 2026 | $2.62B | +12.0% |
| Q4 FY2025 | Dec 31, 2025 | $5.35B | -20.4% |
| Q3 FY2025 | Sep 28, 2025 | $4.60B | -31.4% |
| Q2 FY2025 | Jun 29, 2025 | -$582.00M | – |
| Q1 FY2025 | Mar 30, 2025 | $2.34B | +114.2% |
| Q4 FY2024 | Dec 31, 2024 | $6.72B | +28.3% |
| Q3 FY2024 | Sep 29, 2024 | $6.71B | +94.3% |
| Q2 FY2024 | Jun 30, 2024 | -$1.78B | – |
| Q1 FY2024 | Mar 31, 2024 | $1.09B | -10.1% |
| Q4 FY2023 | Dec 31, 2023 | $5.24B | -38.9% |
| Q3 FY2023 | Oct 1, 2023 | $3.46B | -42.1% |
| Q2 FY2023 | Jul 2, 2023 | -$1.21B | -114.8% |
| Q1 FY2023 | Apr 2, 2023 | $1.21B | -81.5% |
| Q4 FY2022 | Dec 31, 2022 | $8.58B | +45.1% |
| Q3 FY2022 | Oct 2, 2022 | $5.97B | -44.8% |
| Q2 FY2022 | Jul 3, 2022 | $8.17B | -27.7% |
| Q1 FY2022 | Apr 3, 2022 | $6.54B | +44.1% |
| Q4 FY2021 | Dec 31, 2021 | $5.91B | +5.1% |
| Q3 FY2021 | Oct 3, 2021 | $10.83B | +418.1% |
| Q2 FY2021 | Jul 4, 2021 | $11.30B | +217.8% |
| Q1 FY2021 | Apr 4, 2021 | $4.54B | +44.8% |
| Q4 FY2020 | Dec 31, 2020 | $5.63B | +49.2% |
| Q3 FY2020 | Sep 27, 2020 | $2.09B | -53.7% |
| Q2 FY2020 | Jun 28, 2020 | $3.56B | +36.2% |
| Q1 FY2020 | Mar 29, 2020 | $3.13B | +84.5% |
| Q4 FY2019 | Dec 31, 2019 | $3.77B | -20.5% |
| Q3 FY2019 | Sep 29, 2019 | $4.51B | -14.2% |
| Q2 FY2019 | Jun 30, 2019 | $2.61B | -32.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.70B | -14.4% |
| Q4 FY2018 | Dec 31, 2018 | $4.74B | -33.2% |
| Q3 FY2018 | Sep 30, 2018 | $5.26B | +7.6% |
| Q2 FY2018 | Jul 1, 2018 | $3.85B | +18.7% |
| Q1 FY2018 | Apr 1, 2018 | $1.98B | +25.2% |
| Q4 FY2017 | Dec 31, 2017 | $7.09B | +17.3% |
| Q3 FY2017 | Oct 1, 2017 | $4.89B | +3.2% |
| Q2 FY2017 | Jul 2, 2017 | $3.24B | – |
| Q1 FY2017 | Apr 2, 2017 | $1.58B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.04B | – |
| Q3 FY2016 | Oct 2, 2016 | $4.74B | – |
See a number that looks wrong?